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Abstract
Dose-response (or ‘concentration-effect’) relationships commonly occur in
biological and pharmacological systems and are well characterised by Hill
curves. These curves are described by an equation with two parameters: the
inhibitory concentration 50% (IC50); and the Hill coefficient. Typically just the
‘best fit’ parameter values are reported in the literature. Here we introduce a
Python-based software tool,   , and describe the underlying BayesianPyHillFit
inference methods that it uses, to infer probability distributions for these
parameters as well as the level of experimental observation noise. The tool also
allows for hierarchical fitting, characterising the effect of inter-experiment
variability. We demonstrate the use of the tool on a recently published dataset
on multiple ion channel inhibition by multiple drug compounds. We compare the
maximum likelihood, Bayesian and hierarchical Bayesian approaches. We then
show how uncertainty in dose-response inputs can be characterised and
propagated into a cardiac action potential simulation to give a probability
distribution on model outputs.
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1 Introduction
In this article, we describe the approach our software tool takes 
to inferring parameters of dose-response curves from experimental 
data. This introduction addresses the problem, standard approach, 
and our motivation for developing an approach that also character-
ises uncertainty in dose-response parameters, due to variability in 
the data.
1.1 Dose-response curves
‘Dose-response’ (or ‘concentration-effect’) curve-fitting is gener-
ally performed to describe how increasing compound concentra-
tion provokes a response in a process. ‘Dose-response’ generally 
relates to in-vivo experiments where a drug dose is administered 
but the concentration at the relevant site is not precisely known; 
whereas ‘concentration-effect’ generally relates to in-vitro experi-
ments where the concentration is accurately applied. We will refer 
to both as ‘dose-response’ in this article for simplicity. In the case 
study we will pursue, the ‘response’ is binding and blocking of ion 
channels, measured via inhibition of ion currents. Dose-response 
curves are summarised by two parameters: an inhibitory concentra-
tion 50% (IC50) value, that is the concentration of the compound 
that gives 50% of the maximum effect; and a Hill coefficient, which 
sets the ‘steepness’ of the curve as it passes the IC50. Examples of 
dose-response data and a fitted curve are given in Figure 1.
The equation for a dose-response curve was proposed by Hill 
(1910), and subsequently another name for the curve is a Hill curve 
(Weiss, 1997). If we let x be the concentration of a compound, we 
describe the effect of the compound by 
   
( ) 100response ; 50, : ,
50
1
DR Hillf x IC Hill IC
x
= =
 +   
       (1)
where IC50 and Hill are parameters that take positive values. In our 
motivating example this response will be “% block” of a particular 
type of ion channel.
1.2 Standard fitting procedure
A Hill curve is often fitted to all data points simultaneously, to 
obtain ‘average’ IC50 values and Hill coefficients for a particular 
curve. This gives the most likely set of parameter values. For exam-
ple, Crumb et al. (2016) recently published dose-response screen-
ing data for 30 compounds on 7 different ion channels, along with 
best-fit IC50 values and Hill coefficients. But taking this approach, 
there is no associated probability given to these IC50 and Hill val-
ues; different possible ranges for these parameter values are not 
considered. The usual fitting procedure can also give rise to mod-
els which differ in behaviour from each individual experiment, as 
shown by Pathmanathan et al. (2015) in the case of inactivation of 
the fast sodium current in action potential models, and as we will 
show in the case studies below.
1.3 Variability and uncertainty
Real-world experiments exhibit intrinsic and extrinsic variabil-
ity. The characterisation of this variability is becoming of greater 
importance as we move to quantitatively predictive models, par-
ticularly as part of the global cardiac modelling effort (Johnstone 
et al., 2016a; Mirams et al., 2016; Pathmanathan et al., 2015). 
Intrinsic variability describes fluctuations that may be due to inher-
ent randomness, and extrinsic variability describes differences 
between individuals (in this case cells/experiments). Variability 
contributes to uncertainty, but there are other sources of uncertainty 
when modelling and performing experiments (Vernon et al. (2010) 
provide a good introduction). There will also be observation error, 
which arises from imperfect measurements, thus introducing more 
uncertainty.
If we are going to use a model to predict future behaviour, or 
infer some underlying behaviour, we want to study the impact of 
uncertainty and give probabilistic predictions. Here, if there is a 
distribution of parameter values that could have given rise to the 
experimental dose-response data, we would like to capture this 
distribution (uncertainty characterisation). When using these data 
as inputs to further simulations (as discussed below in Section 6) 
we would then construct a distribution of possible outputs corre-
sponding to the distribution of inputs, a process known as uncer-
tainty propagation. The whole process is known as uncertainty 
quantification, or UQ (US National Research Council, 2012), and 
is part of a framework for ensuring safety-critical simulations are 
reliable which is known as validation, verification and uncertainty 
quantification, or VVUQ (Pathmanathan & Gray, 2013).
Figure 1.  A dose-response curve fitted to experimental data for 
hERG block by amiodarone from the Crumb et al. (2016) dataset. 
A dose-response curve is shown fitted to all data points at once with 
a least-square-differences algorithm, with the resulting parameters 
shown at the top of the graph.
      Amendments from Version 1
Version 2 of the manuscript contains four improved figures, and a 
completely new version of Figure 15. Text amended for clarity in 
various places thanks to comments from reviewers.
See referee reports
REVISED
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1.4 Motivation
As part of the Comprehensive in vitro Pro-arrhythmia Assay 
initiative (CiPA, Fermini et al., 2016; Sager et al., 2014), it is pro-
posed that pharmaceutical compounds be tested on up to 7 ion 
channels that both strongly influence ventricular repolarisation and 
are frequently blocked by pharmaceutical compounds. The pro-
posal is for ion channel screening data to be passed into an in silico 
human ventricular action potential model to see if the compound 
produces pro-arrhythmic behaviour, or indicators of such behav-
iour, at the whole-cell level.
In this article we present a software tool to infer distributions of 
possible dose-response curves from experimental data. When mak-
ing predictions of block at a given concentration, these distributions 
of possible dose-response curves provide us with a probabil-
ity distribution for the level of block at that concentration. To 
illustrate the consequences of this, we use the distributions of 
block (for multiple ion channels) inferred from data provided in 
Crumb et al. (2016) as inputs into an in silico action potential 
model. We then run forward simulations to predict a distribution 
of outputs — in this case action potential durations resulting from 
application of a compound at a particular concentration. We show 
that given the limited number of repeats of ion-channel experi-
ments, there are wide ranges of predicted action potentials, with 
overlapping results for different compounds with different associ-
ated pro-arrhythmic risks.
1.5 Our approach
To explore and characterise the uncertainty in the dose- 
response measurements published by Crumb et al., and to propa-
gate these uncertainties into model predictions, we use a Bayesian 
statistical framework to explore different possible dose-
response curves that may have produced these data. Each dose-
response curve is assigned a likelihood score, which, roughly 
speaking, describes how well the curve fits the data. Instead 
of computing point-estimates for the IC50 value and Hill 
coefficient, we infer probability distributions of these parame-
ters, as well as a distribution for the possible observational noise. 
This provides us with a method for propagating uncertainty in 
experimental data into simulations by drawing parameters from 
these inferred distributions, and using these samples as simulation 
inputs.
We describe two different types of Bayesian statistical 
models: one where all data points are treated equally (as 
though they were obtained from the same experiment); and another 
where we believe that each repeat of an experiment has distinct 
properties (through some source of inter-experiment variability) 
and therefore its own set of parameters to infer. The first case we 
will refer to as ‘single-level’, and the second case as ‘hierarchi-
cal’. The single-level case does not consider extrinsic variability, 
since we are assuming that all data points are generated by the same 
behaviour. The hierarchical case does consider extrinsic variabil-
ity, which we model by assuming that each experimental dataset 
was generated according to its own IC50 value and Hill coefficient, 
which may vary across experiments.
2 Bayesian statistical modelling approach
We use a Bayesian framework to quantify the uncertainty present 
in the ion channel screening data. The tool reads in doses in μM, 
but instead of working with IC50 in μM, we work with pIC50, 
where 
    ( ) [ ]( )1050 log Molar 6 log 50 Molar ,pIC IC  = − µ         (2)
with square brackets indicating units. This transformation makes it 
much easier for fitting algorithms to explore the parameter space, as 
linear variation in IC50s does not result in linear changes to dose-
response curves, which are commonly plotted on log scales. The 
dose-response model we therefore work with in practice is 
       
( ) ( )( )6 50% channel block ; 50, : ;10 , .pICDRf x pIC Hill f x Hill−= =
       (3)
So we assume that the underlying behaviour is described by the 
dose-response model, f, given by Equation (3). We assume that 
an experimental observation is Normally distributed around 
some underlying behaviour with some standard deviation, σ (that 
has the same units as the measured response). That is, given an 
applied compound concentration, x, our statistical model is that the 
response, y, is a Normally-distributed random variable with mean 
f(x; pIC50, Hill) and standard deviation σ, that is: 
  ( )( )2; 50, , .y f x pIC Hill σ∼N                        (4)
When we have noisy data, different sets of parameters might 
allow us to fit the equation to the experimental data equally well. 
In our Bayesian framework, we treat these model parameters 
as random variables, in part due to the uncertainty introduced 
through observational error and any parameter identifiability 
problems (see e.g. Daly et al. (2015); Raue et al. (2009); Siekmann 
et al. (2012) for a discussion of how identifiability relates to 
inferred probability distributions). We therefore want to infer a 
probability distribution, instead of point-estimates, for the param-
eters pIC50, Hill and σ. This probability distribution, p(θ |data), is 
the posterior distribution of the parameters, θ, given the observed 
experimental data.
The posterior distribution is defined using Bayes’ Theorem: 
             
( ) ( ) ( )( ) ( )
|
| ,
| d
p data p
p data
p data p
θ
θ θ
θ
θ θ θ
=
∫                        (5)
where p(data|θ) is the likelihood of the parameters θ under our 
model given the observed data y, and p(θ) is the prior distribution 
of the parameters θ. The prior distribution contains our prior knowl-
edge or belief about the parameters before observing any data.
The integral in the denominator of Equation (5) is generally intrac-
table, so we use Markov chain Monte Carlo (MCMC) methods to 
approximate p(θ |data). MCMC methods only require that we can 
evaluate the posterior distribution, pointwise, up to a factor of a 
constant, so it is enough to have that 
	 	 ( ) ( ) ( )| | ,p data p data pθ θ θ∝ 	 																						(6)
to allow us to construct an approximation to the posterior 
distribution.
3 Single-level model
In our example, each experiment consisted of applying one or more 
concentrations of a compound to a cell and measuring the degree of 
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block of an ion current. There were multiple recordings, leading to 
multiple response data-points at each concentration.
3.1 Methods
In this statistical model, we will assume that there is no inter-
experiment variability, so all data points are (effectively) from one 
experiment, and all the data points are generated using the same set 
of parameter values. Under this model, the data for hERG block by 
amiodarone (Crumb et al., 2016), for example, is generated by the 
process schematic shown in Figure 2.
Under our statistical model shown in Figure 2, all data points y(j) 
from a single drug and channel combination are identically inde-
pendently distributed according to 
	 	 ( ) ( )( )( )2; 50, , ,j jy f x pIC Hill σ∼N 	 																						(7)
where x(j) is the applied compound concentration, and j = 1, …, K, 
where K is the total number of data points. The likelihood of the 
parameters pIC50, Hill, and σ, given a single data point y(j) is then 
         
( )( )
( ) ( )( )( )2
22
; 50,1
| 50, , exp .
22
j j
j
y f x pIC Hill
p y pIC Hill σ
σπσ
 −
 = −   
       (8)
In practice, we work with the log of the target distribution, and 
therefore the log of the likelihood given in Equation 8. For more 
details on the implementation, see Johnstone et al., (2016a, 
Supplement B2).
In the data published by Crumb et al., any observations below 
0% or above 100% were capped to 0% or 100%, respectively 
(W. Crumb, personal communication), because these extreme 
values are assumed to be due to observational error. Accordingly, 
we truncate the Normal distribution in Equation (7) at 0 and 100, 
since these are imposed bounds on the data for % channel block (it 
would be better not to filter the data in this way, as, before mak-
ing this adjustment, we observed repeated zero entries leading to 
the erroneous conclusion that there was almost no noise σ on the 
data).
Since pIC50, Hill, and σ are parameters that we infer, we need to 
specify a prior distribution across them, corresponding to p(θ ) in 
Equation (5). We choose independent uniform distributions for 
each parameter, but we could have chosen a more informative prior 
based on previous ion channel screening data, where available. We 
allow Hill to take values in (0,10). The Hill coefficient must be 
positive and describes the steepness of the dose-response curve, so 
after a certain point, increasing the Hill coefficient does not make 
a noticeable difference to the curve, so we choose 10 as a gener-
ous upper bound, above any biologically-plausible drug-binding we 
are aware of. Similarly, a compound that has no measurable effect 
could be thought of as having a very large IC50, and it makes no 
difference practically to model it as having an even larger IC50. 
This corresponds to a negative pIC50 value, and so we choose to 
allow pIC50 to take values in (-1,15) as values outside this inter-
val will not have much effect (see Figure 3). We let σ, which is a 
standard deviation parameter and therefore also positive, take val-
ues in (0,50), where 50 is a generous upper bound for observa-
tional error, which we expect to be closer to 5–10% in practice.
As described in our previous publication (Johnstone et al., 
2016a), we first perform a covariance matrix adaptation evolution 
strategy optimisation (CMA-ES, Hansen et al., 2003) to find 
an optimal starting point for exploring possible parameter sets. 
We then use an adaptive Metropolis-Hastings MCMC algo-
rithm (Haario et al., 2001) to infer p(θ |data), where θ = {pIC50, 
Hill, σ}. Briefly, we want to construct a sequence (Markov chain) 
Figure 2. Statistical model for the generation of dose-response 
data y. All non-shaded variables are parameters for which we wish 
to infer probability distributions. y = {y (1), …, y (K)} is the vector of all 
experimentally-recorded response data points.
Figure 3.  Large IC50 values are indistinguishable when they are 
orders of magnitude above the relevant concentration range. 
Here we show the effect of decreasing pIC50 (increasing IC50), 
while maintaining Hill = 1. The shaded “region of interest” covers 
the minimum and maximum concentrations in the data published 
by Crumb et al.. As pIC50 decreases, there is no significant 
change to the dose-response curve across the relevant range of 
concentrations — all predictions are close to zero response. As 
a result, we somewhat artificially ‘cap’ pIC50 priors to exclude 
pIC50 < −1, otherwise (for datasets with no response signal) 
convergence of minimisation and MCMC algorithms is difficult if not 
impossible.
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of parameter-value sets that approximate samples from the left-
hand-side of Equation (5). A set of parameter values is proposed 
by sampling from a multivariate Normal distribution centred on the 
most recent iteration’s parameter values. The posterior distribution 
(Equation (6)) at these newly-proposed parameter values is then 
computed. The set of these proposed parameter values is accepted 
into the chain with a probability computed as the ratio of posterior 
distribution values between the current parameters and the proposed 
parameters. If the proposed set of parameter values is accepted, it 
is appended to the history of the chain and the next iteration will be 
taken from these new parameter values. As the MCMC algorithm 
runs, the covariance matrix of the proposal distribution skews in the 
directions where more sets of parameters are being accepted into 
the chain. After a large number of iterations, we discard the first 
quarter (or any suitably large fraction) of samples, known as ‘burn-
in’ when the MCMC algorithm was still finding the best regions 
of parameter space. Then we plot normalised histograms of the 
remaining samples to approximate the posterior distribution.
The posterior distribution in the single-level model is given by (up 
to a factor of a constant) 
     
( ) ( )( ) ( ) ( ) ( )150, , | | 50, , 50 ,jKjp pIC Hill p y pIC Hill p pIC p Hill pσ σ σ=∝∏y   (9)
where the first term on the right-hand-side is given by 
Equation (8).
3.2 Results
In Figure 4 we plot normalised marginal and pairwise histograms 
for the values of the parameters for each sample of the MCMC algo-
rithm output, which are approximate projections of the posterior 
distribution across these parameters. The spread in each distribution 
corresponds to the uncertainty in that parameter; if a parameter’s 
marginal posterior distribution is narrower, we are more certain 
about its value from the observed data.
Before propagating these uncertainties, we first draw (pIC50, Hill) 
samples from the MCMC output, and plot dose-response curves 
with these parameter values. Examples are given in Figure 5, where 
amiodarone has a measurable blocking effect on hERG, but no 
measurable effect on Kir2.1. As we take more samples, the plot-
ted curves build up a distribution of possible dose-response curves 
given the experimental data. For each compound concentration, we 
then have a range of possible responses with their relative probabil-
ity densities being given by the density of dose-response curves at 
that concentration.
4 Hierarchical (multi-level/mixture) model
When we plot the ion channel screening data and group the 
data points according to their respective experimental repeats, 
instead of treating them as data points from one experiment as in 
Section 3, we see that data points from the same experiment 
generally keep their relative position. That is, we often see that 
Figure 4. Matrix plot of normalised marginal and pairwise marginal histograms of the MCMC algorithm output samples for each 
parameter, in the amiodarone and hERG example. The well-defined narrow distributions, with lack of cross-correlation, suggest each 
parameter is being successfully inferred from the data.
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Figure 5. Inferred dose-response curves from MCMC (pIC50, Hill) samples. A: amiodarone with measurable effect on hERG. B: amiodarone 
with no measurable effect on Kir2.1. Outside of the range of measured concentrations, the MCMC algorithm was unable to find narrow ranges 
for possible parameter values, because the experimental data does not contain enough information.
the highest value at each concentration was observed during the 
same experiment, as shown for the amiodarone and hERG case in 
Figure 6.
4.1 Methods
The intra-experiment correlation seen in Figure 6 suggests that 
each experiment has its own distinct properties. We model this as 
inter-experiment variability in the pIC50 value and Hill coefficient. 
That is, we treat each experiment as having its own pIC50 and Hill, 
which are drawn from distributions which are shared across experi-
ments. We are assuming that two experiments have different pIC50 
values, say, but that these values are mutually informative. We let N
e
 
be the number of experiments performed. The vector of data points 
obtained from experiment i is yi, where i = 1, …, Ne.
We take a hierarchical approach and assume that there is some 
‘higher-level’ distribution that governs how these parameters vary 
across experiments (see Congdon, 2010, for an introduction to this 
approach).
Hill coefficient and pIC50 distributions for ion channel screen-
ing datasets of up to N
e
 > 12,000 repeats were published in Elkins 
et al. (2013), there they were found to fit independent log-logistic 
and logistic distributions, respectively. We assume the same type of 
distributions would occur here (if the experiments were repeated 
enough): that is, each experiment’s Hilli is drawn from a log-logistic 
distribution with parameters α and β; and each experiment’s pIC50i 
is drawn from a logistic distribution with parameters μ and s. We 
have assumed that the observational errors are drawn from the same 
Normal distribution across all N
e
 repeats, so we infer just a single 
noise standard deviation parameter σ. A schematic of this hierar-
chical statistical model is given in Figure 7, with the ‘mid-level’ 
parameters and ‘bottom-level’ data points being independently dis-
tributed according to 
     Hilli∼log-logistic(α,β ),                 (10)
                   
( )50 logistic , ,ipIC sµ∼
                    (11)
            
( ) ( )( )( )2; 50 , , ,j ji i i iy f x pIC Hill σ∼N
                 (12)
where yi( j) is the jth concentration entry in experiment i’s responses 
yi. We suppose that every experiment i has Ki data points (to 
generalise to cases where different experiments tests different 
numbers of concentrations), so j = 1, …, Ki and i = 1, …, Ne.
We now need to specify prior distributions over the ‘top-level’ 
parameters (in Figure 7): α, β, σ, μ, and s. Prior distributions are 
chosen to contain any prior information or beliefs we have about 
the parameters before observing the data. We can therefore inform 
our choice of prior distributions by considering previously-pub-
lished ion channel screening data. We use gamma distributions for 
all of these, since gamma distributions, in general, only put prob-
ability mass on positive values, and because these parameters are 
all positive, with the exception of μ. μ, however, can take any value 
and represents the centre of the logistic distribution. For μ, we used 
a gamma distribution which is shifted along the x-axis down to -4, 
so there is little probability mass below -2. We choose this because 
as the pIC50 value becomes lower and lower, the IC50 becomes 
larger, and eventually any possible compound effects occur well 
above the experimental concentrations. This was illustrated above in 
Figure 3, where dose-response curves (with Hill = 1) have been 
plotted for varying values of pIC50. The shaded “region of inter-
est” covers the minimum and maximum concentrations in the data 
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Figure 7. Hierarchical statistical model for dose-response data. 
i indexes the individual experiments. All non-shaded variables are 
parameters for which we wish to infer probability distributions.
distributions generated would have no probability mass at 0, and 
also the gradient of the probability density function would be zero. 
This prevents Hill coefficients equal to 0 from being sampled by 
the MCMC algorithm. We also enforce that σ  be greater than 10−3, 
since we believe there is always the possibility of observation error, 
and hence there must be a positive standard deviation, we also run 
into division-by-zero numerical problems with the evaluation of the 
target distribution if we sample σ = 0 (see Equation (8)).
The choice of prior distribution will have an effect on the 
posterior distributions (via Equation (6)). However, the more 
information that is contained in our data, the less effect we expect 
our prior distribution to have on our posterior distribution. For 
example, Figure 9 shows how the marginal posterior distribution 
for the ‘top-level’ parameters correspond to their respective prior 
distributions in the case of synthetic data, where we fit to differ-
ent numbers of experimental datasets. This synthetic data were 
generated by sampling pIC50 values from a logistic distribution 
with μ = 6 and s = 0.1, and Hill coefficients were sampled from a 
log-logistic distribution with α = 1 and β = 5. Normally-distributed 
observation noise with standard deviation σ = 1 was added to the 
dose-response model at every concentration.
We want to infer the posterior probability distribution for α, β, μ, 
s, σ, Hilli and pIC50i, for i = 1, …, Ne, giving a total of 5 + 2Ne 
parameters. Using Bayes’ Theorem, the posterior distribution in 
Equation (6) is now given by 
( )
( ) ( ) ( )( ) ( ) ( ) ( ) ( ) ( )
1 1 1
1
, , , , ,{ } ,{ 50 } |{ }
| , , 50 | , 50 | , .
e e e
e
N N N
i i i i i
N
i i i ii
p s Hill pIC
p Hill pIC p Hill p pIC s p p p p s p
α β µ σ
σ α β µ α β µ σ
= = =
=
∝ ∏
i
i
y
y (13)
We use the same adaptive Metropolis-Hastings MCMC algo-
rithm as in Section 3.1 to infer a posterior distribution from the 
experimental data. Since we have many more parameters than in 
the non-hierarchical case, we expect to have to run our MCMC 
algorithm for more iterations to adequately approximate the poste-
rior distribution. For most cases in this dataset, we have N
e
 = 3 or 
N
e
 = 4, which is not too demanding since our mathematical 
model is a simple analytic expression, and does not require solv-
ing differential equations as our previous work did (Johnstone 
et al., 2016a). However, if N
e
 became very large, we may have to 
use alternative MCMC techniques.
4.2 Implementation
Our tool PyHillFit (Johnstone et al., 2016b) takes a CSV file of 
dose-response points as its input. The file should be comma sepa-
rated values (.CSV) in the following format for each line:
compound name, channel name, experiment number, dose (μM), 
response (% inhibition)
The Monte Carlo algorithms were written in Python using 
NumPy 1.11.0 for numerical linear algebra (van der Walt et al., 
2011), and functions from the SciPy 0.15.1 library (Jones et al., 
2001). Pandas 0.17.1 was used to read the input data csv files 
Figure 6. Data for hERG block by amiodarone suggests 
inter-experiment variability. Different whole-cell patch-clamp 
experiments are plotted with different colours. In this case, the 
responses are consistently in the same ordering relative to the other 
experiments at each compound concentration (e.g. Experiment 2 
always shows the largest response, and Experiment 1 always the 
smallest). This suggests inter-experiment variability that is distinct 
from observational error σ.
published by Crumb et al. Ion channel screening is generally per-
formed at concentrations that range to well-above therapeutic con-
centrations, and so we do not want to infer how a compound will 
behave at even higher concentrations. These gamma prior distribu-
tions were tuned to cover values provided by Elkins et al. (2013), 
but also allow more room for variation. Plots of the prior distribu-
tions for α, β, μ, s, and σ are given in Figure 8.
In addition to covering the values published by Elkins et al., 
we restricted β to be greater than 2, so that all log-logistic 
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Figure 8. Prior distributions. Blue: gamma distributions used as the prior distributions over α, β, μ, s and σ. Grey: histograms of parameter 
estimates for different strongly-blocking control compounds, with large numbers of repeats, as previously published in Elkins et al. (2013). 
However, we want to be able to fit to all compounds, including ineffective ones that elicit no response, hence the increased width of the prior 
distributions on certain parameters (μ particularly).
(McKinney, 2010). cma 1.1.6 was used for initial optimisation 
to find best-fit parameter values (Hansen et al., 2003), which act 
as starting positions for the MCMC algorithms. All figures were 
plotted in matplotlib 1.5.1 (Hunter, 2007) and seaborn 0.7.1 
(http://seaborn.pydata.org/).
PyHillFit output takes the form of files listing samples of the 
posterior distributions for the dose-response curve parameters, 
together with some visualizations of these (as shown throughout 
this article).
4.3 Results
As before, we plot normalised marginal histograms to approxi-
mate the marginal posterior distributions for each parameter. Such 
histograms are plotted for α, β, μ, s, and σ in Figure 10 for the 
amiodarone and hERG case. We can compare these to the prior 
distributions shown in Figure 8, and we see that in most cases we 
have much narrower marginal posterior distributions than prior 
distributions. This tells us that the data contains enough infor-
mation about those parameters to constrain them to narrower 
intervals.
We can also superimpose the normalised histograms for each 
Hilli and pIC50i to give us an idea of how much inter-experiment 
variability is present in these parameters. These superimposed 
histograms are plotted in Figure 11 for the amiodarone and hERG 
case.
To make predictions about how a particular compound and chan-
nel will interact if we perform another experiment, we consider 
the posterior predictive distributions for Hilli and pIC50i. That is, 
what are p(HillNe+1|data) and p(pIC50Ne+1|data)? Since the Hilli and 
pIC50i are modelled as being drawn from log-logistic and logis-
tic distributions, respectively, we sum the log-logistic and logistic 
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Figure 9. A comparison between marginal posterior distributions for ‘top-level’ parameters in the hierarchical model, with their 
respective gamma (Γ) prior distributions. The number of (synthetic) experimental datasets, Ne, being fitted was increased. As we fit to more 
experiments, the prior distributions have a smaller effect on the posterior distributions. Where the black line for the prior distributions looks as 
if it lies along the x-axis (for μ and σ, the prior distribution was much wider than the marginal posterior distribution; there is a lot of information 
on these parameters with just one experiment).
distributions generated from the ‘top-level’ parameters at every 
iteration of our MCMC algorithm output, then normalise them to 
obtain two new probability distributions.
     
( ) ( )1 11| data log-logistic ; , ,e TN t t t tp Hill HillT α β+ =≈ Σ      (14)
                    
( ) ( )1 1150 | data  logistic 50 ; , ,e TN t t t tp pIC pIC sT µ+ =≈ Σ      (15)
where t indexes the samples in our Markov chain, after having dis-
carded a number of initial samples as a burn-in.
These are not necessarily distributions which can be sampled from 
directly, but we can approximately sample from them using the 
inverse-cumulative distribution function (CDF) method. We sum 
and then normalise the individual log-logistic and logistic CDFs. 
After sampling from these new distributions, we plot similar dose-
response curves as in Section 3.2. A plot of predicted dose-response 
curves for a future experiment, following the hierarchical model 
MCMC, is given in plot A of Figure 12. To make a prediction of 
what %-block will be induced by that compound at a particular 
concentration, we take a vertical cross-section through these dose-
response curves and plot a normalised histogram of these levels of 
block to approximate a probability distribution, as shown in plot B 
of Figure 12.
Note that the hierarchical model allows us to make two sets of pre-
dictions. Firstly, using the posterior predictive distribution given 
by Equation (14) & Equation (15) as shown in Figure 12 (panel 
A). This distribution includes inter-experiment variability, and 
can therefore be considered a distribution that predicts where data 
points from future experiments may lie. Secondly, we can exam-
ine the variability in the underlying properties of the compound; 
the ‘average’ effect, before it is altered by inter-experiment vari-
ability (panel B). We generated this plot by taking samples of α 
and μ to use as Hill and pIC50 values. We would expect panel B 
to be more directly comparable with the single-level approach 
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Figure 10. Normalised marginal histograms for the ‘top-level’ parameters, α, β, μ, s, and σ after running the fitting the hierarchical 
model to the amiodarone and hERG dataset using the MCMC algorithm. The red lines indicate the respective prior distributions. Most of 
these distributions are narrower than their respective prior distributions in Figure 8, with the exception of β. We therefore conclude that the 
experimental data does not contain much information about β, in line with the synthetic data study shown in Figure 9.
(which fits ‘average’ data points), which is shown in panel C for 
comparison.
Which of the two distributions (illustrated in panels A or B in 
Figure 12) one may wish to use for predictions is subtle. If we 
consider that the source of variability between experiments is also 
present in the system that we are making predictions for, then the 
first case (panel A) would be the best to use. If however we con-
sider that there is a single underlying effect, and the act of measur-
ing it introduced inter-experiment variability that is not present in 
the real system, then the second distribution (panel B) would be 
more appropriate. Most biological experiments implicitly assume 
the second case is true — that by taking repeated measurements 
and then taking the average, a more accurate assessment of the 
underlying system is made.
5 A comparison of single-level and hierarchical models
There are advantages and disadvantages to choosing either the 
single-level statistical model, or the hierarchical statistical model. 
The main benefit of the single-level model is that we are only 
fitting three parameters, meaning that the parameter space of 
interest is relatively easy to explore. This means that we need to 
run our MCMC algorithm for fewer iterations to obtain an accept-
able approximation of the posterior distribution than if we had a 
larger number of parameters, reducing overall computation time. 
However, a model with an analytic solution such as the one 
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Figure 11. Inferred parameters for individual experiments. Top: 
dose-response curves plotted using the ‘mid-level’ pIC50i and Hilli 
samples from our MCMC algorithm output from the amiodarone 
and hERG dataset. Middle & bottom: superimposed normalised 
histograms for pIC50i and Hilli, after fitting our hierarchical model to 
the amiodarone and hERG dataset using the MCMC algorithm. We 
find that the Hill coefficient does not vary much between experiments, 
however there is variability within the pIC50 value.
we have here (Equation (3)) can be solved very quickly, 
and so computation time is generally not a problem for even the 
hierarchical version of the model, for this application. There 
is also little sensitivity to the prior distributions, as there is a 
lot of information about all three parameters in even one 
experiment.
In Figure 12 we can compare the results of the two types of 
inference for real data on amiodarone block of the hERG current. 
There is a small difference in the predicted curves.
In the single-level case, by fitting to all data points at once, the 
inference can misinterpret inter-experiment variability and assign it 
to the ‘wrong’ parameter(s). To demonstrate this, we generated two 
sets of synthetic data corresponding to these fictitious compounds, 
with fictitious inter-experiment variability properties: 
1.    For shamiodarone, Hill was fixed as 1 across all 
experiments, and the pIC50i were drawn from a logistic 
distribution, with μ = 6 and s = 0.2.
2.    For shamitriptyline, pIC50 was fixed as 6 across all 
experiments, and the Hilli were drawn from a log-logistic 
distribution with α = 1 and β = 2.5.
In both cases, we simulated 5 experiments where each experiment 
consists of measuring % channel block at 4 different compound 
concentrations. We added Normal observation noise with standard 
deviation σ = 0.5 to each point.
Case 1: fixed Hill and varying pIC50
A sample of the inferred curves for this case are given in 
Figure 13. The plots in panels A & D represent pIC50 and Hill 
parameter values being drawn from their respective posterior 
predictive distributions; this gives predictions of how we believe 
the observations from a future experiment would behave. The plots 
in B & E are based on α and μ samples — what we believe to 
be the underlying ‘average’ behaviour of the compound interacting 
with an ion channel, when experimentally-introduced variability is 
discounted. The hierarchical model was able to identify consist-
ency within the Hilli, and the MCMC algorithm generally only 
infers that pIC50i varied between experiments.
The histograms in Figure 13 (panels D–F) are a cross-section of 
the dose-response curves at different concentrations, and represent 
the probability density of % block at that compound concentra-
tion. Note that each curve in panel B has approximately the same 
slope, corresponding to a consistent Hill coefficient, whereas in 
panel C we see that there is a greater range of slopes, correspond-
ing to (slightly more) variability in the Hill coefficient. Compar-
ing plot E with plot F, we see that at 0.05 μM concentration, the 
non-hierarchical model is less certain about the % channel block 
than the hierarchical model, because the former has incorrectly 
inferred there is more variation in the Hill coefficient. So the 
single-level model tends to compensate for the varying parameter 
values by fitting curves that fit through an ‘average’ of the points. 
The algorithm does this by varying both Hill and pIC50 to obtain 
curves that could fit the data reasonably well, even when the 
synthetic data were generated by holding one parameter fixed and 
varying the other.
Case 2: fixed pIC50 and varying Hill
A sample of the inferred curves for this case are given in 
Figure 14. The single-level model in panel C does show small 
variability in the Hill coefficient, as well as small variability in 
the IC50 (and hence pIC50). This leads to a reasonably spread 
prediction of ion channel block at both a concentration near pIC50 
and at a higher concentration (panel F). But we know that the 
underlying data had the same pIC50, and so variability near the 
IC50 should be minimal, and indeed the spread of predictions at 
a higher concentration should be larger. The hierarchical model 
captures the desired underlying variability better (compare 
panels E and F). The Hill coefficient varies (panel B) while also 
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Figure 12. Predicted dose-response curves and associated probability distributions for levels of block at example concentrations 
when fitting to the amiodarone and hERG dataset. A: Hierarchical model — predictions for how a future experiment will behave, with 
samples taken from the posterior predictive distributions. B: Hierarchical model — inferred distribution for the underlying behaviour of the 
system, plotted by using μ and α samples from the MCMC algorithm output directly as values for pIC50 and Hill, respectively. C: Single-level 
— inferred distribution, plotted by taking samples from the MCMC algorithm output. D,E,F: Histograms of the intersections between the 
vertical lines and dose-response curves in A,B,C, respectively, at two different concentrations of amiodarone.
Figure 13. Inference on synthetic data generated by fixing Hill = 1 and varying pIC50. A: Predicted dose-response curves, with pIC50 
and Hill sampled from their respective posterior predictive distributions, taking inter-experiment variability into account. B: Inferred underlying 
behaviour of the compound-ion channel interaction, with inter-experiment variability discounted. C: Inferred dose-response curves from 
single-level inference. D–F: Normalised histograms of the cross sections plotted with vertical lines in plots A–C. These histograms represent 
probability density functions of % block at a particular concentration, given the (synthetic) experimental data.
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Figure 14. Inference on synthetic data generated by fixing pIC50 and varying Hill. A: Predicted dose-response curves, with pIC50 and 
Hill sampled from their respective posterior predictive distributions, taking inter-experiment variability into account. B: Inferred underlying 
behaviour of the compound-ion channel interaction, with inter-experiment variability discounted. C: Inferred dose-response curves from 
single-level inference. D–F: Normalised histograms of the cross sections plotted with vertical lines in plots A–C. These histograms represent 
probability density functions of % block at a particular concentration, given the (synthetic) experimental data.
capturing the low variability in the pIC50 value (there is still 
some variability in the inferred pIC50 distribution due to obser-
vational noise and a low number of repeat experiments). As a 
result, the predicted percentage blocks in panels E and F are 
different. As for Case 1, either too-much or too-little variability 
is predicted by the single-level inference, depending on the 
concentration.
6 Propagating dose-response uncertainty
The proposed Comprehensive in-vitro Pro-arrhythmia Assay 
(CiPA) recommends the use of computational action potential 
models in the drug safety process. Ion channel screening will be 
performed, and the IC50 values and Hill coefficients obtained from 
these experiments are to be used in action potential models to pre-
dict whether or not a compound is likely to be pro-arrhythmic. One 
simple proposed measure of pro-arrhythmia is action potential 
duration prolongation (Mirams et al., 2011), directly related to 
prolongation of the QT-interval, which can be a precursor to 
potentially fatal arrhythmias such as Torsade de Pointes.
Using best-fit IC50 values and Hill coefficients obtained from ion 
channel screening data, we can compute a predicted level of block 
of each of the ion currents in an action potential model, at a particu-
lar compound concentration. We then simulate an action potential 
and measure the action potential duration prolongation relative to 
the control case (see Beattie et al. (2013) for an example of this 
approach). However, when using best-fit IC50 values and Hill 
coefficients, we obtain a single predicted action potential after 
simulating a particular compound concentration.
Instead, we use our tool to infer probability distributions for each 
experiment’s IC50 value and Hill coefficient. Each sample is 
‘equally likely’, but there will be more samples around the regions 
of greater probability density. We can then randomly take samples 
from these distributions and compute an action potential duration 
for each sample. Again, each output is ‘equally likely’, but there 
will be more outputs close to each other where there is the greatest 
probability density. This allows us to construct a probability distri-
bution for predicted action potential durations based on the original 
ion channel screening data (uncertainty propagation).
To illustrate the proposed uncertainty propagation we use our tool to 
fit hierarchical dose-response parameters to thirty drug compounds 
for seven ion currents each using the Crumb et al. (2016) dataset 
supplied with the code associated with this article. We then take 
500 samples from the MCMC output for each drug and channel 
combination, based on the ‘underlying effects’ curves from hier-
archical fits (see Figure 12, Figure 13 & Figure 14), and simulate 
action potential durations after applying seven ion channel block 
using the approach outlined in Mirams et al. (2011). We plot the 
resulting predicted action potential duration distributions as violin 
plots in Figure 15. A violin plot for each of the thirty compounds 
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Figure 15. Violin plots of prediction action potential duration (APD90, time taken for the cell to return to 90% repolarisation after 
depolarisation) using 500 samples from the iterations of our MCMC algorithm under the hierarchical statistical model. Simulations 
were run using the O’Hara et al. (2011) human ventricular cardiomyocyte action potential model, and APD90s were computed. We used 
‘AP-predict’ (Williams & Mirams, 2015), a bolt-on project for the Chaste open-source computational biology C++ library (Mirams et al., 2013). 
Violin distribution plots are shown for each of the 30 compounds discussed by Crumb et al. In one case, several samples led to very long 
action potentials and so the y-axis is cut off early for clarity.
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is coloured according to the Torsade/QT risk categorisation in the 
CredibleMeds database (https://crediblemeds.org/). We also plot 
the control action potential duration in the O’Hara model along 
with a 10% action potential duration prolongation.
We see that the vast majority of the compounds have overlap-
ping probability distributions for predicted APD at maximum free 
therapeutic plasma concentration, suggesting that at least this 
previously-proposed measure will be insufficient to distinguish 
compounds in terms of risk based on data such as these.
This suggests that either: action potential prolongation is not a 
good enough marker of pro-arrhythmia; or, there was too much 
uncertainty associated with the experimental data to constrain these 
distributions to narrow distinct ranges. To counter the latter point, 
we suggest that more experimental repeats be performed. In either 
case, it is imperative to realise that the data being used have a level 
of uncertainty which means it is not possible to rank the majority of 
these drugs in terms of their predicted APD.
7 Discussion
A Bayesian framework is a useful tool to address uncertainty 
characterisation in ion channel screening data. When no uncer-
tainty characterisation is performed, one can obtain best-fit 
parameter values for the data presented, but there is no associated 
probability in terms of the behaviour that generated the data, or 
in predictions informed by the data. The single-level Bayesian 
inference model can provide ranges of possible dose-response 
curves (and underlying parameters) that fit ion channel screen-
ing data. But parameter-specific inter-experiment variability can 
be missed when using a ‘single-level’ statistical model, as the 
algorithm treats all points equally and so varies the parameters 
without considering the inter-experiment correlations. This leads 
to an ‘averaging’ effect, where the dose-response model is fitting 
to an average of the experimental data points, but may not reflect 
the behaviour of any individual experiment. However, this 
single-level inference is quick to run as it only requires fitting 
3 parameters, and provides a better approximation of probability 
distributions than a single best-fit.
A hierarchical statistical model can capture inter-experiment vari-
ability within certain dose-response parameters, as demonstrated 
in the synthetic cases discussed in Section 5. The hierarchical 
model can therefore be used to infer inter-experiment behav-
iour, and hence predict how a future experiment might behave. 
By taking samples for the ‘top-level’ parameters from our MCMC 
output, we can build distributions of how we believe the com-
pound is interacting with the ion channel. At a given compound 
concentration, we then have a probability distribution for possible 
levels of ion channel block. The hierarchical model is able to deter-
mine what variability is being introduced at the experimental level, 
and allows us to make probabilistic statements about the underlying 
behaviour.
Our hierarchical model is similar to nonlinear mixed effects 
(NLME) modelling, but we operate in a Bayesian framework. 
NLME assumes a similar structure to that shown in Figure 7, but 
infers best-fit values for the ‘top-level’ parameters, and a distribu-
tion from which the ‘mid-level’ parameters are sampled. While it 
does capture inter-experiment variability and would allow us to 
make predictions about how a future experiment might behave, it 
only provides a point-estimate for underlying behaviour, rather than 
different possibilities with relative probabilities.
A possible limitation of the hierarchical model is that computa-
tion time increases with the number of experimental datasets being 
fit to at once. This is not a problem for up to 4 or 5 experiments, 
but the number of parameters quickly becomes intractable for the 
adaptive-Metropolis MCMC algorithm that we have been using. In 
general, with MCMC methods, we want to run our algorithm for 
as long as possible, to best approximate samples from the posterior 
distribution. There is therefore no upper limit for how long this 
method takes, although for these examples we have run our algo-
rithm for 500,000 iterations, which takes approximately 12 minutes 
for the amiodarone-hERG case which has 3 experimental datasets 
of 4 concentrations each.
Another possible limitation of the hierarchical model is the depend-
ence on the prior distributions for the ‘top-level’ parameters. As 
shown in Figure 9, when there is not much data, the posterior is 
heavily influenced by the prior. However, we chose our priors based 
on data published by Elkins et al. which was based on 12,000 ion 
channel screening experiments, and we therefore have some confi-
dence in their shapes (Figure 8). In a Bayesian framework, should 
new data become available, we can compute new posterior distri-
butions for the parameters according to Equation (5), by using a 
previous posterior distribution as the new prior distribution.
A benefit of both inference techniques is that we introduce the 
observation noise as a parameter to be fitted, along with the pIC50 
values and Hill coefficients. Instead of estimating the observa-
tion noise and then fitting dose-response curves based on our esti-
mate, we allow the MCMC algorithm to find likely levels of noise, 
while also quantifying the uncertainty in those estimates. Since all 
of these parameters are being fit at the same time by the MCMC 
algorithm, we can extract how much noise on dose-response 
parameters is introduced by inter-experiment variability, and how 
much noise is due to observation error.
7.1 Conclusions
Single best-fit parameter estimates from ion channel screening 
data can give a most likely set of dose-response curve parame-
ters. However, this approach does not provide us with a measure 
of uncertainty around these parameters. The software tool we 
present can quantify some of the uncertainty associated with 
dose-response curves, with its default priors set for ion channel 
screening data, for the purposes of propagating this uncertainty 
into further quantitative studies.
Data and software availability
Latest source code and datasets used in the publication: https://
github.com/mirams/PyHillFit
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Archived source code and datasets as at the time of publication: 
https://doi.org/10.5281/zenodo.237643 (Johnstone et al., 2016b)
License: BSD 3-Clause
The code contains the experimental input data required to reproduce 
the examples shown here in comma separated value (CSV) format 
in the file data/crumb_data.csv. Installation instructions for 
the tool and its dependencies can be found in the README file, in 
the main folder at the above links.
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appreciated by those generating those data, especially when that data is further propagated in in silico
models of cardiac tissues. The authors have written and formatted the article very effectively to make the
manuscript understandable and approachable. Given the availability of computational tools such as
Python it is now also much more practical to perform these analyses and appropriately quantify the
uncertainty. The practice of reporting 'best-fit' parameter values may have been the best which could
practically be achieved previously. It may also have been a model sufficient for many questions but the
developing need to use these data in computational models of tissues for safety purposes requires a
more robust treatment of uncertainty. Simply carrying forward best-fit values and generating point
estimates of effects on tissues and point estimates of margins between therapeutic drug concentrations
and concentrations impacting cardiac tissues may not adequately serve drug development and regulatory
assessment.
 
In the practice of electrophysiology screening experiments some compromises are made in order to make
the experiments both quick enough and inexpensive enough to meet the drug discovery process. This will
often mean that a limited range of concentrations are tested and a minimum number of individual
experimental repeats are made. When calculating 'best-fit' parameters some values are 'fixed' to make
calculating the key parameter IC50 possible e.g. fixing minimum current inhibition to 0%, maximum
inhibition to 100% and the Hill Slope to 1. The manuscript describes some of the potential issues which
may result from such compromises. There are also hidden impacts of experimental design. As an
example the experiment may call for following compound effect for as long as necessary to reach a
steady state effect. As the kinetics of channel block are concentration dependent this means that steady
state will occur more slowly at low concentrations. In addition to drug effect there is also often current
'run-down' or 'run-up' evident in these experiments. The 'run-down' effect is the more common. This
means that at low concentrations of compound the observed effect may have a larger contribution of
'run-down' than at larger concentrations. This serves to somewhat flatten the Hill Slope and left shift the
IC50 from 'truth'. Alternatively, fixed durations of observation may be applied at each concentration. As
the norm is to try and minimize the overall duration of the recording this may mean that compound effect
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 IC50 from 'truth'. Alternatively, fixed durations of observation may be applied at each concentration. As
the norm is to try and minimize the overall duration of the recording this may mean that compound effect
is under estimated at low concentrations leading to the Hill slope becoming steeper and the IC50 being
slightly right shifted. Some electrophysiologists may choose to have uniform long compound application
periods or use run-down correction techniques to minimize these experimental impacts on parameter
estimates. The significant value of the current manuscript is that it allows the data from the experiments to
be used in their most raw form without the compromises described. It leverages priors based on previous
experimental information.  It gives the key information as a probability distribution rather than a single
value. It also serves to illustrate the uncertainty and give the opportunity to generate more data for those
compounds which show promise and where more certainty is desirable.
 
There is one key outstanding element which the current manuscript cannot address. In this experimental
context it is the assessment of the kinetics of block. When relating the effect of a compound to how it may
impact a tissue when the underlying kinetics of the ion channel experiment and that of the ionic current in
a tissue under the normal heart rates differ cannot be captured in an IC50 value or Hill slope even taking
into account the uncertainty. This will likely require different experimental voltage-clamp paradigms and
the estimation of at least one further parameter. That said that parameter estimate then becomes
accessible to the types of calculation described here. 
 
Overall this is a very well thought out piece of work, well written and with a potentially useful piece of
software described.
 
This review is based on my personal professional opinion.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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Summary of the Paper
In this manuscript Johnstone propose a new tool (PyHillFit) for fitting dose response curves from et al 
cardiac ion channels. This tool uses Bayesian inference methods to determine the distributions of the
parameters. They investigate two alternative models, one that ignores inter-experimental variability and a
second hierarchical model that characterises variability. Using a recently published dataset of inhibition of
multiple ion channels they demonstrate the use of the tool and how experimental variability propagates
through to the fitted dose response curves. They then extend these to simulations using a cardiac action
potential model to show the distribution of model outputs.
The benefits of a hierarchical Bayesian approach are clearly demonstrated. The paper describes the tool
and its underlying model and assumptions well, but could benefit from further development of the
arguments around the cardiac action potential distribution.
Main Comments
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 1.  
2.  
3.  
Main Comments
The most interesting part of the paper was propagating the uncertainty though the action potential
simulations. The authors conclude that this measure is insufficient to distinguish compounds in terms of
risk (Fig 15), but if the distributions were plotted so that they are not on top of each other it may indeed be
possible to distinguish the compounds. For example, "caterpillar plots", boxplots, or violin plots (e.g. Fig 2
in  ) would better show the result.http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0096431
The authors also do not attempt to classify the compounds on the basis of their distribution (e.g. >50% of
the distribution over a 10% prolongation of APD(90) to indicate risk of TdP) and so demonstrate how poor
(or good) the distributions are as a predictive tool. The manuscript would be strengthened with this
additional information.
Minor Comments
It is unclear why the PyHillFit package was developed as these models can be easily fit with existing
MCMC software such as JAGS or Stan. Furthermore, using existing MCMC software allows other models
to be fit (e.g. 4 parameter logistic models -- when the upper and lower asymptote are not rescaled to
100% and 0%), and the sampling may be more efficient (especially with Stan, which handles hierarchical
models well). The benefits of PyHillFit over these other tools should be highlighted.
The data are analysed with two models but the verbal description of the models is ambiguous. There are
three models that could be run:
Parameters (IC50 and Hill) are common for all experiments (complete pooling, corresponding to
the first model)
 
Parameters are different for all experiments; each experiment has its own parameter estimated
independently from the other experiments (no pooling; not used in this paper)
 
Parameters are different for all experiments, but shared across experiments and thus mutually
informative (partial pooling; the second model)
It is clear from the equations that their second model is number 3 above, but the verbal description is that
of number 2. Please clarify the verbal description.
Other minor suggestions and corrections
Figures 2 and 7 should have a shaded "x" node pointing into "y", as y depends not just on
parameters but on other observed data.
 
Figure 2, and Eq 7. Is this across all compounds and channels or separately for each compound
and channel combination?
 
Figure 10 might benefit from a line showing the prior distributions to allow easy comparison of prior
and posterior.
 
Figures 12 (A-C), 13 (A-C), 14 (A-C) would be clearer if the data points were plotted above the
distribution curves
 
Not clear how many cardiac action potential simulations are used to generate the distributions for
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 Not clear how many cardiac action potential simulations are used to generate the distributions for
Figure 15. Surely not the 375,000 samples from the posterior?
 
Author contributions: RJH should be RHJ?
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 27 Feb 2017
, Gary Mirams
We would like to thank the reviewers for their thoughtful, insightful and careful review, we have
uploaded a second version of the manuscript which we hope is improved in light of their
comments.
> The most interesting part of the paper was propagating the uncertainty though the action
potential simulations. The authors conclude that this measure is insufficient to distinguish
compounds in terms of risk (Fig 15), but if the distributions were plotted so that they are not on top
of each other it may indeed be possible to distinguish the compounds. For example, "caterpillar
plots", boxplots, or violin plots (e.g. Fig 2 in
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0096431) would better show the
result.
Thank you for the suggestion, we have updated Figure 15 to use a violin plot. This does
allow a better inspection of the distributions and their overlap, as we can now see more
clearly, there is still substantial overlap.
> The authors also do not attempt to classify the compounds on the basis of their distribution (e.g.
>50% of the distribution over a 10% prolongation of APD(90) to indicate risk of TdP) and so
demonstrate how poor (or good) the distributions are as a predictive tool. The manuscript would be
strengthened with this additional information.
This is something we specifically tried to avoid, partly because it becomes a large exercise
that detracts from the main software tool, and also not least because the risk of TdP is not
well-defined or agreed upon for some of these compounds. Our point isn't that the
distributions will help/hinder predictions per-se, rather you could easily be anywhere 'within'
a distribution, so wherever they overlap there will necessarily be no way to reliably
distinguish between compounds. If the 50% value happened to be a good classifier for
these data, we would still not expect this to hold for new compounds, as the ordering could
easily reverse when new data become available wherever the distributions overlap to this
extent. Nevertheless, we annotated Figure 15 with risk classifications from the
CredibleMeds database (a more credible data source than its name suggests!). As one
might expect, only the clear shorteners and prolongers correspond well to ‘no known risk’ or
‘known TdP risk’; the majority of compounds have overlapping distributions of moderate
APD prolongation, that cannot really be ranked reliably.
> It is unclear why the PyHillFit package was developed as these models can be easily fit with
existing MCMC software such as JAGS or Stan. Furthermore, using existing MCMC software
allows other models to be fit (e.g. 4 parameter logistic models -- when the upper and lower
asymptote are not rescaled to 100% and 0%), and the sampling may be more efficient (especially
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 asymptote are not rescaled to 100% and 0%), and the sampling may be more efficient (especially
with Stan, which handles hierarchical models well). The benefits of PyHillFit over these other tools
should be highlighted.
PyHillFit is intended for the specific case of ion channel screening data. We do appreciate
that this could have been coded in Stan, but we wanted to have more ‘control’ over what
was happening below the surface, and in how the results were outputted and analysed, so
we wrote the algorithms ourselves in Python. Perhaps as much of our ‘work’ here was in
deriving the statistical model and appropriate prior distributions, as it was in writing the
software itself. If a 4 parameter agonist compound was identified then an extension in Stan
to cover this might be appropriate.
> The data are analysed with two models but the verbal description of the models is ambiguous...it
is clear from the equations that their second model is number 3 above, but the verbal description is
that of number 2. Please clarify the verbal description.
Text amended in section 4.1.
> Other minor suggestions and corrections
We appreciate these being pointed out and have made the suggested amendments:
>    Figures 2 and 7 should have a shaded "x" node pointing into "y", as y depends not just on
parameters but on other observed data.
Updated, thanks for the suggestion.
>    Figure 2, and Eq 7. Is this across all compounds and channels or separately for each
compound and channel combination?
Separately, text updated.
>    Figure 10 might benefit from a line showing the prior distributions to allow easy comparison of
prior and posterior.
Updated, thanks for the suggestion.
>    Figures 12 (A-C), 13 (A-C), 14 (A-C) would be clearer if the data points were plotted above the
distribution curves
Updated, thanks for the suggestion.
>    Not clear how many cardiac action potential simulations are used to generate the distributions
for Figure 15. Surely not the 375,000 samples from the posterior?
Now mentioned in the caption.
>    Author contributions: RJH should be RHJ?
Updated(!), well spotted!
 No competing interests were disclosed.Competing Interests:
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